NEUROCRINE BIOSCIENCES INC 10-Q

Item 5. Other Information During the period from January 1, 2026 to March 31, 2026, our officers (as defined in Rule 16a-1(f) under the Exchange Act) and/or directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below: Name and Title Action* Date Trading Arrangement Total Shares Authorized to be Sold**** Expiration Date Rule 10b5-1** Non-Rule 10b5-1*** David Boyer Adoption 2/23/2026 X 33,832 2/23/2027 Chief Corporate Affairs Officer Julie Cooke Adoption 3/2/2026 X 36,937 12/31/2026 Chief Human Resources Officer Ingrid Delaet Adoption 2/27/2026 X 51,818 2/28/2027 Chief Regulatory Officer Kyle Gano Adoption 2/4/2026 X 60,000 2/6/2027 Chief Executive Officer Kevin Gorman Adoption 2/17/2026 X 245,088 2/6/2027 Director Jude Onyia Adoption 2/25/2026 X 22,000 2/15/2027 Chief Scientific Officer Richard Pops Adoption 2/13/2026 X 30,000 8/15/2026 Director Stephen Sherwin Adoption 3/5/2026 X 25,000 6/4/2027 Director Matthew Abernethy Termination 1/20/2026 X 3,618 2/28/2028 Chief Financial Officer Termination 1/20/2026 X 2,704 2/28/2027 Termination 1/20/2026 X 1,283 2/15/2026 Eric Benevich Termination 1/20/2026 X 3,168 2/28/2028 Chief Commercial Officer Termination 1/20/2026 X 2,196 2/28/2027 Termination 1/20/2026 X 1,207 2/15/2026 David Boyer Termination 1/20/2026 X 2,490 2/28/2028 Chief Corporate Affairs Officer Termination 1/20/2026 X 1,910 2/28/2027 Termination 1/20/2026 X 1,104 2/15/2026 Julie Cooke Termination 1/20/2026 X 2,265 2/28/2028 Chief Human Resources Officer Termination 1/20/2026 X 1,592 2/28/2027 Termination 1/20/2026 X 916 2/15/2026 Ingrid Delaet Termination 1/20/2026 X 2,265 2/28/2028 Chief Regulatory Officer Termination 1/20/2026 X 1,432 2/28/2027 Termination 1/20/2026 X 422 2/15/2026 Kyle Gano Termination 1/20/2026 X 3,618 2/28/2028 Chief Executive Officer Termination 1/20/2026 X 2,704 2/28/2027 Termination 1/20/2026 X 1,541 2/15/2026 Kevin Gorman Termination 1/20/2026 X 9,036 2/28/2028 Director Termination 1/20/2026 X 5,664 2/28/2027 Termination 1/20/2026 X 2,707 2/15/2026 Darin Lippoldt Termination 1/20/2026 X 3,258 2/28/2028 Chief Legal Officer Termination 1/20/2026 X 2,196 2/28/2027 Termination 1/20/2026 X 1,250 2/15/2026 Jude Onyia Termination 1/20/2026 X 4,341 2/28/2028 Chief Scientific Officer Termination 1/20/2026 X 2,864 2/28/2027 Termination 1/20/2026 X 2,457 2/15/2026 ______________ * The Rule 10b5-1 trading arrangements reflected in the termination rows dated January 20, 2026 were sell-to-cover arrangements authorizing the pre-arranged sale of shares to satisfy employee tax withholding obligations arising exclusively from the vesting of restricted stock units (RSUs) and performance restricted stock units (PRSUs) and the related issuance of shares. These arrangements were terminated in connection with the Company's transition to net share settlement of RSUs and PRSUs, pursuant to which the Company withholds from the shares otherwise issuable upon settlement a number of shares sufficient to satisfy applicable tax withholding obligations and issues the remaining net shares to the award recipient. Shares withheld under net share settlement are not sold in market transactions. 59 ** Intended to satisfy the affirmative defense of Rule 10b5-1(c) *** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) **** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards. 60 Item 6. Exhibits The following exhibits are filed as part of, or incorporated by reference into, this report: Exhibit 3.1 Description: Certificate of Incorporation, as amended Reference: Incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2018 3.2 Description: Bylaws, as amended Reference: Incorporated by reference to Exhibit 3.2 of the Company's Quarterly Report on Form 10-Q filed on October 30, 2024 4.1 Description: Form of Common Stock Certificate Reference: Incorporated by reference to the Company’s Registration Statement on Form S-1 (Registration No. 333-03172) 31.1 Description: Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 31.2 Description: Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934 32* Description: Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Description: Inline XBRL Instance Document. – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Description: Inline XBRL Taxonomy Extension Schema Document. 101.CAL Description: Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Description: Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Description: Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Description: Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Description: Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101) ______________ * These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. Except as specifically noted above, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K have a Commission File Number of 000-22705. 61 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: May 5, 2026 /s/ Matthew C. Abernethy Matthew C. Abernethy Chief Financial Officer (Duly authorized officer and Principal Financial Officer) 62